2025 AGM and Scientific Conference
[EM id=4022]
-
-
2024 AGM and Scientific Conference
[EM id=3996]
-
Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study
Imoro Zeba Braimah ,Ernest Kenu ,Kwesi N. Amissah-Arthur ,Stephen Akafo ,Kwaku Oppong Kwarteng ,Winfried M. Amoaku| Published: October 24, 2019 Abstract Aim To evaluate the safety of 1.25mg and 2mg intravitreal ziv-aflibercept (IVZ) in Ghanaian eyes with choroido-retinal vascular diseases. Design Prospective, randomised, double blind, interventional study. Methods Twenty patients with centre involving macular oedema…
-
Cardiovascular disease implicated in rapid glaucoma progression
To further understand the systemic and ocular risk factors for rapid glaucoma progression, investigators examined a cohort of rapid and nonrapid disease progressors. Study design Investigators compared medical histories and clinical features of 54 rapidly progressing glaucoma eyes (β₯1dB mean deviation (MD)/year) with 486 non-rapidly progressing eyes(<1 dB MD/yr). All patients underwent at least 5…
-
Should we image all patients with third nerve palsy?
This retrospective, population-based study assessed the incidence and etiologies of acquired third nerve palsy among newly diagnosed patients. Study design Investigators identified all newly diagnosed cases of acquired third nerve palsy from 1978 through 2014 using the Rochester Epidemiology Project, a record-linkage system of medical records for all patient-physician encounters in Olmsted County, Minnesota. Outcomes…
-
Discovery of new angiogenic factor may enhance treatment for retinal disease
Scientists from Massachusetts Eye and Ear have identified a new transcription factor involved in retinal neovascularization: Runt-related transcription factor 1 (RUNX1). The findings could lead to new therapies for conditions involving abnormal vessel growth within the retina, such as proliferative diabetic retinopathy (PDR). In a report published online in Diabetes, the authors showed that RUNX1…
-
Low-cost ziv-aflibercept appears safe for intraocular administration
A multicenter study adds evidence that intravitreal ziv-aflibercept, a low-cost formulation of aflibercept originally developed as a systemic chemotherapy agent, is safe for treatment of retinal diseases. Study design Investigators from 3 centers enrolled 60 consecutive patients (65 eyes) with neovascular AMD, DME, CME associated with CRVO, or pseudophakic CME. Subjects received 6 or more…
-
Telemedicine screening confirms acute ROP is typically symmetrical
In this secondary analysis of the Telemedicine Approaches to Evaluating Acute-phase ROP (e-ROP) study, investigators examined the intereye agreement of ROP features and severity using trained nonphysician graders. Study design The NIH-funded e-ROP study evaluated the feasibility of telemedicine to identify infants with referral-warranted ROP, defined as the presence of stage 3 or above, plus…
-
Early findings hint at safety, efficacy of stem-cell therapy for keratoconus
Β The growing field of autologous stem-cell therapy has set its sights on another potential ocular target: corneal dystrophies. A Spanish and Lebanese research team has completed a phase 1 pilot study demonstrating that autologous adipose-derived stem cells (ADSCs) can survive transplantation into the corneal stroma and produce new collagen. The investigative therapy is designed to…
-
Timing of IOL repositioning surgery significantly impacts refractive outcomes
This large retrospective study analyzed the incidence and appropriate timing of repositioning surgery to correct misalignment of toric IOLs. Study design The retrospective, multicenter case series included 6,431 eyes who received acrylic foldable toric IOLs after phacoemulsification. Outcomes included rate and timing of IOL repositioning, as well as residual IOL misalignment, refractive outcome and need…
